Christopher Flowers, MD: This patient’s situation addressed one of the key unmet needs with follicular lymphoma, and that’s patients who experience early relapse. I’ve been engaged in a US intergroup trial that evaluates those 3 arms with therapies for those patients who experience early relapse. I think that’s a very important trial to accrue patients to, to help answer this question.
The other unmet needs that are being addressed are those patients with aggressive forms of relapse or transformation.
CAR [chimeric antigen receptor] T cells are another promising therapy that is available for patients with follicular lymphoma, and I think new trials need to be explored to ascertain where those might be best utilized in the relapsed and refractory setting, particularly for patients who experience more aggressive disease.
There are now many new, novel targeted immunotherapies for patients with follicular lymphoma, and we’re moving into an era where chemotherapy-free regimens may be possible for patients in the first line of therapy and with each subsequent line of relapse.
It’s a very promising time for new therapies and new clinical trials for patients with follicular lymphoma.
Transcript edited for clarity.
Case:A 77-Year-Old Man With Follicular Lymphoma